10226-29-6

Basic information

• Product Name: 1-Bromo-5-hexanone
• Synonyms: 1-bromo-5-hexanone;6-Bromohexan-2-one;4-Bromobutyl methyl ketone;5-Oxohexyl BroMide;2-Hexanone, 6-bromo-
• CAS NO: 10226-29-6
• Molecular Formula: C₆H₁₁BrO
• Molecular Weight: 179.05494
• EINECS: 233-544-4
• Product Categories: Aliphatics;Miscellaneous Reagents
• Mol File: 10226-29-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 216°C (rough estimate)
• Flash Point: 78.2 °C
• Appearance: /
• Density: 1.3494
• Vapor Pressure: 0.0784mmHg at 25°C
• Refractive Index: 1.4890 (estimate)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 1-Bromo-5-hexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-5-hexanone(10226-29-6)
• EPA Substance Registry System: 1-Bromo-5-hexanone(10226-29-6)

Safety Data

• Hazardous Substances Data: 10226-29-6(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Oil

Uses

6-Bromo-2-hexanone (cas# 10226-29-6) is a compound useful in organic synthesis.

InChI:InChI=1/C6H11BrO/c1-6(8)4-2-3-5-7/h2-5H2,1H3

Upstream product

• 151417-64-0 6-bromohexan-2-ol 
• 1191-30-6 5-bromopentanal 
• 676-58-4 methylmagnesium chloride 
• 111-29-5 1 ,5-pentanediol 
• 1073-06-9 3-fluorobromobenzene 
• 21746-88-3 4-epoxy-2-yl-bromobutane 
• 854657-89-9 2-(3-ethoxy-propyl)-acetoacetic acid ethyl ester 
• 2695-47-8 6-Bromo-1-hexene 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 130250-58-7 5-bromo-N-methoxy-N-methylpentanamide 
• 10226-28-5 ethyl 6-methyl-3,4-dihydro-2H-pyran-5-carboxylate 
• 21856-89-3 6-hydroxy-2-hexanone 
• 10035-10-6 hydrogen bromide 
• 1462-03-9 1-methylcyclopentanol 

Downstream Products

• 109-49-9 5-Hexen-2-one 
• 412320-65-1 1-ethyl-6-methyl-1,2,3,4-tetrahydro-pyridine 
• 67886-01-5 6-(phenylsulfonyl)-2-hexanone 

Relevant articles and documents

A direct retro-Barbier fragmentation

-

A novel galantamine-curcumin hybrid as a potential multi-target agent against neurodegenerative disorders

The acetylcholinesterase (AChE) inhibitors are the main drugs for symptomatic treatment of neurodegenerative disorders like Alzheimer’s disease. A recently designed, synthesized and tested hybrid compound between the AChE inhibitor galantamine (GAL) and the antioxidant polyphenol curcumin (CU) showed high AChE inhibition in vitro. Here, we describe tests for acute and shortterm toxicity in mice as well as antioxidant tests on brain homogenates measured the levels of malondialdehide (MDA) and glutathione (GSH) and in vitro DPPH, ABTS, FRAP and LPO inhibition assays. Hematological and serum biochemical analyses were also performed. In the acute toxicity tests, the novel AChE inhibitor given orally in mice showed LD50 of 49 mg/kg. The short-term administration of 2.5 and 5 mg/kg did not show toxicity. In the ex vivo tests, the GAL-CU hybrid performed better than GAL and CU themselves; in a dose of 5 mg/kg, it demonstrates 25% reduction in AChE activity, as well as a 28% and 73% increase in the levels of MDA and GSH, respectively. No significant changes in blood biochemical data were observed. The antioxidant activity of 4b measured ex vivo was proven in the in vitro tests. In the ABTS assay, 4b showed radical scavenging activity 10 times higher than the positive control butylhydroxy toluol (BHT). The GAL-CU hybrid is a novel non-toxic AChE inhibitor with high antioxidant activity which makes it a prospective multitarget drug candidate for treatment of neurodegenerative disorders.

Ring-opening iodination and bromination of unstrained cycloalkanols through ?-scission of alkoxy radicals

Ring-opening iodination or bromination of unstrained cycloalkanols with NaI or NaBr and PhI(OAc)2 under visible light irradiation is developed. In this protocol the concentration of I2is modulated through the generation of triiodide (I3-), thus significantly avoiding undesired side reactions. The reaction is under mild conditions and has a wide substrate scope, thus providing a practically useful method for accessing ω-iodo or ω-bromoketones.